Gastrointestinal Perforation After Treatment With Tocilizumab: An Unexpected Consequence of COVID-19 Pandemic

被引:11
作者
Rojo, Mikel [1 ]
Cano-Valderrama, Oscar [1 ,2 ]
Picazo, Sara [1 ]
Saez, Carlos [1 ]
Gomez, Lorena [1 ]
Sanchez, Cristina [1 ]
Sanz-Ortega, Gonzalo [1 ,2 ]
Torres, Antonio J. [1 ,2 ]
机构
[1] Hosp Clin San Carlos, Dept Surg, C Prof Martin Lago SN, Madrid 28040, Spain
[2] Univ Complutense Madrid, Dept Surg, Madrid, Spain
关键词
D O I
10.1177/0003134820926481
中图分类号
R61 [外科手术学];
学科分类号
摘要
引用
收藏
页码:565 / 566
页数:2
相关论文
共 3 条
[1]   Tocilizumab treatment in COVID-19: A single center experience [J].
Luo, Pan ;
Liu, Yi ;
Qiu, Lin ;
Liu, Xiulan ;
Liu, Dong ;
Li, Juan .
JOURNAL OF MEDICAL VIROLOGY, 2020, 92 (07) :814-818
[2]   Tocilizumab (Actemra) [J].
Sheppard, Martin ;
Laskou, Faidra ;
Stapleton, Philip P. ;
Hadavi, Shahryar ;
Dasgupta, Bhaskar .
HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2017, 13 (09) :1972-1988
[3]   Brief Report: Risk of Gastrointestinal Perforation Among Rheumatoid Arthritis Patients Receiving Tofacitinib, Tocilizumab, or Other Biologic Treatments [J].
Xie, Fenglong ;
Yun, Huifeng ;
Bernatsky, Sasha ;
Curtis, Jeffrey R. .
ARTHRITIS & RHEUMATOLOGY, 2016, 68 (11) :2612-2617